Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: Rationale and design of the Defibrillator After Primary Angioplasty (DAPA) Trial

American Heart Journal

Volumn 152, Issue 4, 2006, Pages 636-640

  Ottervanger, Jan Paul ^a   Ramdat Misier, Anand R ^a   Zijlstra, Felix ^b   Schalij, Martin J ^c   Wever, Eric ^d   Jordaens, Luc J L M ^e   Henriques, Jose P S ^f   de Boer, Menko Jan ^a   Robbe, Hindrik W J ^g   Wellens, Hein J J ^h  

^a ISALA HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g Medtronic   (Netherlands)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DEFIBRILLATION; DEFIBRILLATOR; FOLLOW UP; HEART INDEX; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HOSPITALIZATION; METHODOLOGY; MORTALITY; MULTICENTER STUDY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; STANDARD; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CROSS-OVER STUDIES; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; RESEARCH DESIGN; SAMPLE SIZE; TIME FACTORS;

EID: 33748707780     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.06.012     Document Type: Article

References (39)

1. McMurray J., Kober L., Robertson M., et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 (2005) 525-530
2. Domanski M.J., Exner D.V., Borkow C.B., et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol 33 (1999) 598-604
3. Teo K.K., Mitchell L.B., Pogue J., et al. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure and left ventricular dysfunction. Circulation 110 (2004) 1413-1417
4. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
5. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
6. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med 335 (1996) 1933-1940
7. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced heart failure. N Engl J Med 350 (2004) 2140-2150
8. Bardy G.H., Lee K.L., Mark D.B., et al., for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
9. PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow-up and analysis of individual patient data from randomized trials. Am Heart J 145 (2003) 47-57
10. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
11. Yap Y.G., Duong T., Bland M., et al. Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. Eur Heart J 14 (2005) 1385-1393
12. De Luca G., van 't Hof A.W.J., Ottervanger J.P., et al. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J 26 (2005) 662-666
13. De Luca G., Suryapranata H., Dambrink J.H.E., et al. Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: data from the Zwolle Myocardial Infarction study. Am Heart J 148 (2004) 852-856
14. Mehta R.H., Harjai K.J., Cox D., et al. Primary angioplasty in myocardial infarction (PAMI) investigators. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 42 (2003) 1739-1746
15. Haager P.K., Christott P., Heussen N., et al. Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by markers of myocardial reperfusion. J Am Coll Cardiol 41 (2003) 532-538
16. Henriques J.P.S., Zijlstra F., Ottervanger J.P., et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 23 (2002) 1076-1078
17. Fath-Ordoubadi F., Huehns T., Al-Mohammad A., et al. Significance of the thrombolysis in myocardial infarction scoring system in assessing infarct-related artery reperfusion and mortality rates after acute myocardial infarction. Am Heart J 134 (1997) 62-68
18. Ross A.M., Coyne K.S., Moreyra E., et al. Extended mortality benefit of early postinfarction reperfusion. Circulation 97 (1998) 1549-1556
19. Gibson C.M., Cannon C.P., Murphy S.A., et al., for the European Cooperative Study Group. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101 (2000) 125-130
20. Lenderink T., Simoons M.L., Es van G., et al., for the European Cooperative Study Group. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation 92 (1995) 1110-1116
21. Lincoff A.M., Topol E.J., Califf R.M., et al., for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Am J Cardiol 75 (1995) 871-876
22. Anderson J.L., Karagounis L.A., and Califf R.M. Meta-analysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 78 (1996) 1-8
23. Cura F.A., L'Allier P.L., Kapadia S.R., et al. Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol 88 (2001) 124-128
24. Simoons M.L., Vos J., Tijssen J.G.P., et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 14 (1989) 1609-1615
25. Halkin A., Singh M., Nikolsky E., et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 45 (2005) 1397-1405
26. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
27. Hohnloser S.H., Kick K.H., Dorian P., et al. Randomized trial of prophylactic implantable cardioverter defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
28. Wilber D.J., Zareba W., Hall W.J., et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 109 (2004) 1082-1084
29. Richter S., Duray G., Gronefeld G., et al. Prevention of sudden cardiac death. Lessons from recent controlled trials. Circ J 69 (2005) 625-629
30. Elhendy A., Chapman S., Porter T.R., et al. Association of myocardial ischemia with mortality and implantable cardioverter-defibrillator therapy in patients with coronary artery disease at risk of arrhythmic death. J Am Coll Cardiol 46 (2005) 1721-1726
31. Bigger Jr. J.T., and for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 337 (1997) 1569-1575
32. Bigger Jr. J.T., Whang W., Rottman J.N., et al. Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 99 (1999) 1416-1421
33. Dorian P., Connolly S., and Hohnloser S.H. Why don't ICDS decrease all-cause mortality after MI? Insights from the DINAMIT study (abstract). Circulation 110 Suppl III (2004) III-502
34. Gronefeld G., Thorpe K.E., Connolly S.J., et al. Competing risks for arrhythmic versus non-arrhythmic death in prophylactic ICD therapy early after myocardial infarction (abstract). Circulation 110 Suppl III (2004) III-502
35. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival, after acute myocardial infarction. N Engl J Med 329 (1993) 1615-1622
36. Chesebro J.H., Knatterud G., Roberts R., et al. Thrombolysis in myocardial infarction (TIMI) trial, phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76 (1987) 142-154
37. de Boer M.J., Reiber J.H.C., Suryapranata H., et al. Angiographic findings and catheterisation laboratory events in patients with primary coronary angioplasty or streptokinase therapy for acute myocardial infarction. Eur Heart J 16 (1995) 1347-1356
38. van der Horst I.C., Zijlstra F., van 't Hof A.W.J., et al. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 42 (2003) 784-791
39. Snapinn S.M. Monitoring clinical trials with a conditional probability stopping rule. Stat Med 11 (1992) 659-672